RxDoctor Payments Data

Patrick Kuhlman

Hematology & Oncology · Greenville, SCNPI 1386064640

Payments from drug & device makers

$14,020in general payments, 2019–2025

Across 126 payments — averaging $111.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • AstraZeneca$610
  • Seagen Inc.$330
  • Novartis$268
  • Galvanize Therapeutics, Inc$222
  • Gilead$209
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$3,72593%
  • Education$2957%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,020 in reported general payments places this provider in the 60th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$105,539
Medicare patients
299
Services billed
1,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide54$657,012
LenvimaLenvatinib Mesylate22$488,011
CabometyxCabozantinib S-Malate14$261,210
Abiraterone Acetate116$251,821
RevlimidLenalidomide12$212,579
LonsurfTrifluridine/Tipiracil Hcl16$182,893
CreonLipase/Protease/Amylase22$62,384
EliquisApixaban103$58,886
XareltoRivaroxaban26$21,957
Potassium Chloride98$1,915
Gabapentin38$1,221
Oxycodone Hcl93$1,202
Anastrozole28$832
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$705
Klor-Con M20Potassium Chloride35$555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$128$657,01254 claims
Eisai Inc.Lenvima$16$488,01122 claims
Exelixis Inc.Cabometyx$13$261,21014 claims
Bristol Myers SquibbRevlimid$73$212,57912 claims
AbbVieCreon$20$62,38422 claims
PfizerEliquis$10,158$58,886103 claims
Johnson & JohnsonXarelto$173$21,95726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →